South Korea’s Kolon Life Science Inc. has granted Mitsubishi Tanabe Pharma Corp. exclusive rights to develop and commercialize in Japan Invossa, the world's first cell-mediated gene therapy for osteoarthritis (OA), in a deal worth KRW500bn ($437.8m) plus sales royalties.
"Through this latest deal, Invossa's value and technology have been recognized. Invossa’s successful advance into the Japanese market, which is...








